Charles Schwab Investment Management Inc Rain Therapeutics Inc. Transaction History

Charles Schwab Investment Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	SELL	$0.82 - $1.42 $5,625 - $9,741	-6,860 Reduced 15.02%	38,822 $33,000
Q2 2023 Aug 09, 2023	BUY	$1.09 - $9.93 $49,793 - $453,622	45,682 New	45,682 $54,000
Q2 2022 Aug 15, 2022	SELL	$2.21 - $5.56 $76,088 - $191,425	-34,429 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$5.07 - $13.68 $16,051 - $43,310	-3,166 Reduced 8.42%	34,429 $175,000
Q4 2021 Feb 11, 2022	BUY	$11.91 - $17.0 $222,693 - $317,866	18,698 Added 98.95%	37,595 $485,000
Q2 2021 Aug 16, 2021	BUY	$15.08 - $20.3 $284,966 - $383,609	18,897 New	18,897 $294,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.